X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.prnewswire.com/news-releases/amgen-to-submit-teprotumumab-marketing-authorization-application-to-the-european-medicines-agency-302128358.html
https://www.fiercepharma.com/pharma/amgen-expects-revenue-bump-its-acquisition-horizon-between-324b-and-338b
https://endpts.com/horizon-adds-severe-hearing-impairment-warning-to-blockbusters-label/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761143
https://www.fiercebiotech.com/biotech/viridian-therapeutics-looks-over-horizon-new-phase-12-eye-disease-data
https://ir.horizontherapeutics.com/news-releases/news-release-details/tepezzar-teprotumumab-approved-brazil-treatment-active-thyroid
https://ir.horizontherapeutics.com/news-releases/news-release-details/new-data-tepezzar-teprotumumab-trbw-clinical-trials-and-real
https://www.reuters.com/markets/deals/amgen-set-buy-biotech-firm-horizon-26-bln-valuation-bloomberg-news-2022-12-12/?rpc=401&
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761143
https://www.pharmaceutical-technology.com/news/xeris-horizon-partnership-teprotumumab/
https://endpts.com/horizon-lowers-expectations-for-tepezza-and-adjusts-its-strategy-for-the-year-ahead/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761143
https://www.businesswire.com/news/home/20211012005280/en/New-TEPEZZA%C2%AE-teprotumumab-trbw-Data-to-be-Presented-at-the-American-Academy-of-Ophthalmology-AAO-2021-Annual-Meeting
https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-provides-preliminary-2020-financial
https://www.fiercepharma.com/manufacturing/horizon-faces-tepezza-disruptions-as-manufacturer-catalent-tapped-for-warp-speed
https://www.biospace.com/article/releases/new-tepezza-teprotumumab-trbw-data-to-be-presented-at-the-american-academy-of-ophthalmology-2020-annual-meeting/
https://www.prnewswire.com/news-releases/agc-biologics-and-horizon-therapeutics-plc-expand-partnership-301163318.html
https://www.fiercepharma.com/pharma/horizon-notches-fda-approval-for-rare-eye-disease-med-tepezza
https://endpts.com/fda-expert-panel-unanimously-recommends-approval-for-horizon-therapeutics-eye-drug/
https://seekingalpha.com/news/3505317-horizon-therapeutics-phase-3-trial-finds-significant-benefit-teprotumumab
https://www.fiercepharma.com/marketing/horizon-bulks-up-salesforce-ahead-750m-inflammatory-eye-drug-launch
https://www.businesswire.com/news/home/20190426005127/en/New-Data-Phase-3-Teprotumumab-Trial-OPTIC/?feedref=JjAwJuNHiystnCoBq_hl-WFAllVCLJFCqzlmaJ8DKHU4plfPZtlGYRDUHCSmgbii6XkLWuQZD-HgGRnjQvCyg3iCfEFIaJW7-otp9V1XQiK2eHTJy3ZqOEt7kKgLu20J
https://www.fiercebiotech.com/biotech/new-phase-3-data-paints-fuller-picture-for-horizon-s-teprotumumab-aace
http://www.pmlive.com/pharma_news/horizon_sunny_as_thyroid_eye_disease_drug_hits_the_mark_1279828
https://endpts.com/after-thyroid-eye-drug-scores-in-phiii-test-horizon-pharma-readies-marketing-application/
Market Place
Share 
